Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 13Neoplasms, Plasma Cell 3Recurrence 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 2Waldenstrom Macroglobulinemia 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Polyneuropathies 1Paraproteinemias 1Mouth Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Endocrine System Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Thalidomide × Clear all
NCT00450008 2016-03-17

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Terminated
9 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡